No Data
No Data
Microchip Convertible Bonds: The conversion price was adjusted from 25.36 yuan/share to 25.26 yuan/share, and stock conversion resumed on June 4
Shenzhen Microchip Biotechnology Co., Ltd. announced that due to a reduction in the total share capital due to the cancellation of shares, the “Microchip Convertible Bonds” conversion price was adjusted from 25.36 yuan/share to 25.26 yuan/share. The adjustment will take effect from June 4, 2024. “Microchip Bonds Transfer” will stop swapping shares on June 3, 2024, and resume share swaps on June 4.
Microchip Biotech (688321.SH): The company currently has capital reserves of about 1 billion yuan
Gelonghui, May 17丨Microchip Biotech (688321.SH) recently said during a survey from institutional investors that the company currently has about 1 billion yuan in capital reserves, including cash on hand, bank financial management, and issued but not yet fully used bond funds. The R&D investment in the next two years is expected to be about the same as last year. Since clinical trials are carried out in stages, capital investment is also gradually increasing, so it is possible to avoid spending a large amount of money at once. The company focuses on improving the efficiency of capital use and controlling costs by optimizing clinical trial design and operation. The company adopts strategies to reduce costs and increase efficiency to ensure continuous research
Microchip Biotech (688321.SH): Prices of sidabendamide and siglitazide are expected to remain relatively stable over the next two years
Gelonghui, May 17丨Microchip Biotech (688321.SH) recently said during a survey receiving institutional investors that the PTCL indications for sidabonamide have now been included in national health insurance for the fourth time, and the DLBCL indications were approved at the end of April. They are in line with the conditions for participating in national health insurance negotiations in the second half of this year, and additional indications are included in medical insurance. How to maintain access to medicines and the profitability of the company through health insurance negotiations is an ongoing task of the company. The company expects the prices of sidabendamide and siglitazide to remain relatively stable over the next two years.
Microchip Biotech: The current resale amount of “Microchip Bonds Transfer” is 0 yuan
Shenzhen Microchip Biotechnology Co., Ltd. announced that according to data provided by the Shanghai branch of China Securities Registration and Settlement Co., Ltd., during the current “Microchip Bond-to-Bond” resale filing period, the number of valid resale declarations was 0, and the resale amount was 0 yuan.
Microchip Biotech (688321.SH): Application for phase III clinical trial of sidabendamide for colorectal cancer accepted
Microchip Biotech (688321.SH) issued an announcement. The company recently received from the Drug Evaluation Center of the State Drug Administration...
Microchip Biotech (688321): Big Indications Drive High Growth, Cash Flow Turns Losses into Profits
New products drive high growth. The company achieved revenue of 130 million yuan in 2024Q1, up 23% year on year, mainly due to increased sales of siglitazide sodium. Product sales increased 666% year on year, and sales revenue increased 3127 year on year
No Data